Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bendamustine vs Ruxolitinib Conditioning in Haploidentical HSCT
NCT06477549Phase 2Recruiting
- Sponsor
- First Saint Petersburg State Medical University
- Start
- Jun 2024
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bendamustine in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL) and 3 more (2 arms), sponsored by First Saint Petersburg State Medical University. Primary endpoint: Event-free survival at 2 years. Started Jun 2024; status: recruiting.
02
Drugs
bendamustine
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)Myeloproliferative Neoplasm (MPN)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06477549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06477549.